Size | Price | |
---|---|---|
Other Sizes |
ln Vitro |
L-norleucine, a leucine isomer, has a particular effect on protein synthesis in skeletal muscle. L-norleucine exhibits antiviral action. L-norleucine interacts with the hnRNPA2/B1 protein, decreasing the expression of two E-cadherin inhibitors, Twist1 and Snail, while increasing E-cadherin expression and inhibiting tumor spread [2].
|
---|---|
References |
|
Additional Infomation |
L-norleucine is a non-proteinogenic L-alpha-amino acid comprising hexanoic acid carrying an amino group at C-2. It does not occur naturally. It is a 2-aminohexanoic acid and a non-proteinogenic L-alpha-amino acid. It is a conjugate acid of a L-2-aminohexanoate. It is an enantiomer of a D-norleucine. It is a tautomer of a L-2-aminohexanoic acid zwitterion.
Norleucine is under investigation in clinical trial NCT00081952 (Amino Acid Therapy for Hot Flashes in Postmenopausal Women). L-Norleucine has been reported in Daphnia pulex, Arabidopsis thaliana, and other organisms with data available. An unnatural amino acid that is used experimentally to study protein structure and function. It is structurally similar to METHIONINE, however it does not contain SULFUR. |
Molecular Formula |
C6H13NO2
|
---|---|
Molecular Weight |
131.17292
|
Exact Mass |
131.094
|
CAS # |
327-57-1
|
Related CAS # |
L-Norleucine-d9;1331889-36-1
|
PubChem CID |
21236
|
Appearance |
White to off-white solid powder
|
Density |
1.0±0.1 g/cm3
|
Boiling Point |
234.0±23.0 °C at 760 mmHg
|
Melting Point |
300ºC
|
Flash Point |
95.3±22.6 °C
|
Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
Index of Refraction |
1.465
|
LogP |
0.92
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
3
|
Rotatable Bond Count |
4
|
Heavy Atom Count |
9
|
Complexity |
93.1
|
Defined Atom Stereocenter Count |
1
|
SMILES |
CCCC[C@@H](C(=O)O)N
|
InChi Key |
LRQKBLKVPFOOQJ-YFKPBYRVSA-N
|
InChi Code |
InChI=1S/C6H13NO2/c1-2-3-4-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m0/s1
|
Chemical Name |
(2S)-2-aminohexanoic acid
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~5 mg/mL (~38.12 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 2.86 mg/mL (21.80 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 7.6237 mL | 38.1185 mL | 76.2369 mL | |
5 mM | 1.5247 mL | 7.6237 mL | 15.2474 mL | |
10 mM | 0.7624 mL | 3.8118 mL | 7.6237 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.